DiscoverResearch To Practice | Oncology VideosER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders
ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders

ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders

Update: 2025-11-05
Share

Description

Featuring an interview with Prof Patrick Neven, including the following topics:

  • Emergence of ESR1 mutations in ER-positive, HER2-negative breast cancer (0:00 )
  • Observed toxicity profile of oral selective estrogen receptor degraders (SERDs) (3:57 )
  • Emerging data with novel oral SERD combinations (6:31 )
  • Challenges for a general medical oncologist in breast cancer (8:41 )
  • Sequencing and selection of therapies in ER-positive, HER2-negative breast cancer (12:16 )
  • Evaluating the strategy of switching to an oral SERD during first-line endocrine therapy upon "molecular progression" (23:16 )

CME information and select publications

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders

ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders

Dr. Neil Love